Targeting Macromolecules to CNS and Other Hard-to-Treat Organs Using Lectin-Mediated Delivery

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Delivery

Background:

• Macromolecular drugs face significant challenges in reaching intracellular targets and crossing biological barriers like the blood-brain barrier (BBB).
• Effective delivery to organs such as the central nervous system (CNS), bone, and eye is crucial for treating various diseases but remains a major hurdle.
• Novel strategies are needed to overcome these delivery limitations and improve therapeutic efficacy.

Purpose of the Study:

• To investigate the potential of Ricin Toxin B subunit (RTB) lectin as a novel strategy for macromolecule delivery.
• To evaluate RTB lectin's ability to mediate cellular uptake and transport across biological barriers.
• To explore RTB lectin's therapeutic implications for CNS diseases.

Main Methods:

• Utilized RTB lectin, a non-toxic carbohydrate-binding subunit of ricin toxin, known for its affinity to cell surface glycolipids and glycoproteins.
• Investigated RTB lectin's endocytic uptake mechanisms in mammalian cells, including adsorptive-mediated and receptor-mediated pathways.
• Conducted in vivo biodistribution studies in lysosomal storage disease models.

Main Results:

• RTB lectin demonstrated efficient endocytic uptake into mammalian cells via multiple routes.
• In vivo studies showed RTB-lectin transporting therapeutic enzymes across the blood-brain barrier in models of lysosomal storage diseases.
• Evidence supports RTB-lectin's capability to deliver corrective enzyme doses to the CNS.

Conclusions:

• RTB lectin shows promise as a versatile vehicle for macromolecule delivery across challenging biological barriers.
• This lectin-mediated delivery system has significant implications for developing protein-based therapeutics for CNS-involved diseases.
• RTB lectin offers a potential solution to enhance drug efficacy and address unmet needs in treating neurological disorders.